Investors

Calando Pharmaceuticals, Inc. has been funded by Arrowhead Research Corporation since 2004. Arrowhead Research Corporation is a holding company that forms, acquires, and operates portfolio companies commercializing innovative nano- technologies. By working closely with leading scientists and universities, Arrowhead identifies the latest advances in nanotechnology and matches them with product development opportunities in high-growth markets.

Arrowhead is currently focused on developing innovative therapies at the interface of biology and nanoengineering to cure disease and improve human health. Providing strategic management, financing, and operational services to its portfolio companies, Arrowhead takes an active role in their development, keeping the business and technical development teams at the portfolio level focused on near term revenue opportunities and capital efficiency. Arrowhead’s strategy is to maintain or build a majority ownserhip position in each portfolio company, thus providing significant exposure to their growth. Arrowhead’s ultimate goal is to monetize the value of its subsidiaries through an initial public offering of subsidiary stock or a sale of a subsidiary to another company. Alternatively, Arrowhead could retain ownership of subsidiary to capture its continuing cash flow and income.

   Arrowhead owns a 79% stake in Calando Pharmaceuticals, Inc.